Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling for hair loss should avoid anti-inflammatory supplements like garlic, Vitamin E, fish oil, turmeric, and NSAIDs for 3 days before and 5 days after the procedure to enhance collagen production. Completely abstaining from these supplements may be unnecessary, but caution is advised around the procedure time.

Hair loss discussion focuses on adding an anti-androgen to stack with topical finasteride. Eucapil (fluridil) is suggested for its safety and minimal side effects.

GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.

The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.

The conversation discusses reducing hair fall by addressing dandruff with anti-dandruff shampoo, regular oiling, and stress management through meditation and yoga. Other users mention using ketoconazole, vitamin D, and finasteride, with some experiencing side effects.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

The user is experiencing white flakes on their scalp despite using anti-dandruff shampoos and oils for six weeks. A suggestion was made to try ketoconazole at higher concentrations, as it might be seborrheic dermatitis, which can lead to hair loss if untreated.

A user shared their 3-month progress using 1mg oral finasteride daily and 5% topical minoxidil twice daily, along with Pura D’Or anti-thinning shampoo and a scalp massager. They noticed initial worsening but later saw hair follicle recovery.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.